Sarepta lifts 2026 sales outlook as exon-skippers outsell Elevidys nearly three to one

Sarepta Therapeutics reported third-quarter net product revenue of about $323.8m on 5 November, with most of it coming from its older exon-skipping medicines rather than its gene therapy. The PMO portfolio contributed $240.3m, against $83.5m for Elevidys, so the PMO products were roughly 2.9 times the gene therapy's sales in the period.

The company raised the bottom of its 2026 net product revenue guidance by $50m. The range is now $1.25bn to $1.3bn, which narrows it from below. It also cut the upper limit of its expense guidance by $25m. The summary does not give the underlying expense figures, so the size of the revised range cannot be stated here.

Attention now moves to the pipeline. Sarepta expects multiple ascending dose data in the fourth quarter of 2026 for SRP-1003 in myotonic dystrophy type 1 and SRP-1001 in facioscapulohumeral muscular dystrophy. It said it is preparing Phase 3 programmes for both and talking to the US Food and Drug Administration about accelerated and traditional approval. The available material does not describe trial designs, timelines or the agency's stance.

For context, accelerated approval generally rests on a surrogate or intermediate endpoint thought reasonably likely to predict clinical benefit, and it usually carries an obligation to run confirmatory trials. Which route Sarepta pursues, and what the quarter's data show, has not been disclosed.